Drug
Pyrazinamide clinical trials
Also written Zinamide.
- studies test it
- 40
- open now
- 9
- in phase 3
- 13
- first study started
- 2000
Keep track of what changes. Save the Pyrazinamide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Z
- 3
Studies by the year they started
40 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 18
- Phase 3
- 13
- Phase 4
- 5
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 38
Global Alliance for TB Drug Development (8) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · University College, London (2) · Beijing Chest Hospital (2) · University of Cape Town (1) · GlaxoSmithKline (1) · Médecins Sans Frontières, France (1) · Seoul National University Hospital (1)
Often tested with
Tested in the same studies.
Isoniazid (21) · Rifampin (20) · Ethambutol (18) · Bedaquiline (13) · Moxifloxacin (13) · Pretomanid (9) · Linezolid (6) · Levofloxacin (5)
Studies
Open first, then newest update. How each study uses Pyrazinamide is read from its arms, and is right about nine times in ten.
Testing it · 40
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBRecruitingPhase 2University College, LondonNCT06114628Written as Pyrazinamide (Z)
- Re-evaluating the Duration in Children of TB TreatmentNot yet recruitingPhase 2University of Wisconsin, MadisonNCT07656012Written as Pyrazinamide
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCTNot yet recruitingPhase 2Ministry of Health, Saudi ArabiaNCT07467252Written as Pyrazinamide and Hydroxychloroquine (AI-Optimised)
- A PAN-USR TB Multi-Center TrialRecruitingPhase 3Shenzhen Third People's HospitalNCT06905522Written as Pyrazinamide (Z)
- PanACEA - STEP2C -01RecruitingPhase 2Michael HoelscherNCT05807399Written as Pyrazinamide
- Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)Not yet recruitingPhase 3University College, LondonNCT07163143Written as Pyrazinamide (Z)
- Intensified Short Course Regimen for TBM in AdultsNot yet recruitingPhase 3Indian Council of Medical ResearchNCT05917340Written as Pyrazinamide
- A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in ChinaRecruitingPhase 4Beijing Chest HospitalNCT05306223Written as Pyrazinamide
- Sitafloxacin-containing Regimens for Shortening Tuberculosis TreatmentNot yet recruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT05454345Written as Pyrazinamide
- Tuberculosis Treatment Shortening TrialCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00130247Written as Pyrazinamide
- Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult PatientsCompletedPhase 2/3Global Alliance for TB Drug DevelopmentNCT03338621Written as Pyrazinamide
- Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and PyrazinamideSuspendedPhase 2University Hospital, LinkoepingNCT04694586Written as pyrazinamide
- Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary TuberculosisCompletedPhase 2GlaxoSmithKlineNCT05382312Written as RIFAFOUR e-275
- Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary TuberculosisTerminatedPhase 2Gates Medical Research InstituteNCT05971602Written as Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
- Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated TuberculosisActive, not recruitingPhase 3University of Cape TownNCT04951986Written as Rifampicin, Pyrazinamide, Ethambutol and Isoniazid
- Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With TuberculosisTerminatedPhase 2Thirty Respiratory LimitedNCT06041919Written as HRZE
- Evaluating Newly Approved Drugs for Multidrug-resistant TBCompletedPhase 3Médecins Sans Frontières, FranceNCT02754765Written as Pyrazinamide
- A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary TuberculosisCompletedPhase 2Global Alliance for TB Drug DevelopmentNCT04179500Written as pyrazinamide
- Treatment Shortening of MDR-TB Using Existing and New DrugsCompletedPhase 2Seoul National University HospitalNCT02619994Written as Pyrazinamide
- Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUSCompletedNot applicableHuashan HospitalNCT04717908Written as Pyrazinamide
See all 40 studies that test Pyrazinamide →
Given in every arm · 26 — Pyrazinamide is usual care beside what is tested
- A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)Not yet recruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT07595042Written as Pyrazinamide
- Shortened Regimen for Drug-susceptible TB in ChildrenRecruitingPhase 3Johns Hopkins UniversityNCT06253715Written as Pyrazinamide
- Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous MeningitisRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05383742Written as Pyrazinamide (PZA)
- Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible TuberculosisNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07129629Written as Pyrazinamide (PZA)
- Ultra-Short Regimen for Elderly DS-TBNot yet recruitingPhase 3Shenzhen Third People's HospitalNCT07076225Written as Pyrazinamide (Z)
- Short-Course Anti-tuberculosis Regimens for Mild Spinal TuberculosisNot yet recruitingPhase 2Shandong UniversityNCT06917495Written as Pyrazinamide
- Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)Not yet recruitingPhase 3Seoul National University HospitalNCT04485156Written as Pyrazinamide
- Short-course Regimens for the Treatment of Pulmonary TuberculosisActive, not recruitingPhase 2/3Centers for Disease Control and PreventionNCT05766267Written as Pyrazinamide
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of TuberculosisCompletedPhase 3Centers for Disease Control and PreventionNCT02563327Written as Pyrazinamide
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)CompletedPhase 2University of Massachusetts, WorcesterNCT04930744Written as Pyrazinamide
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TuberculosisActive, not recruitingPhase 2Brigham and Women's HospitalNCT05556746Written as Pyrazinamide (PZA)
- Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST StudyTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04311502Written as Pyrazinamide
- StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With TuberculosisCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03882177Written as Rifafour
- Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive TuberculosisCompletedPhase 2/3University College, LondonNCT03474198Written as Pyrazinamide
- Assessing PA-824 for Tuberculosis (the APT Trial)CompletedPhase 2Johns Hopkins UniversityNCT02256696Written as Pyrazinamide
- A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary TuberculosisCompletedPhase 3St George's, University of LondonNCT02581527Written as Pyrazinamide
- Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in IndonesiaCompletedNot applicableUniversity of GiessenNCT02554318Written as Pyrazinamide
- An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant TuberculosisCompletedPhase 2/3University of Cape TownNCT02454205Written as Pyrazinamide
- Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3CompletedPhase 4ANRS, Emerging Infectious DiseasesNCT02057796Written as Rifampin, isoniazid, pyrazinamide, ethambutol
- Rosuvastatin Evaluation as a Tuberculosis Treatment AdjunctStatus unknownPhase 2National University Hospital, SingaporeNCT04504851Written as Pyrazinamide
Showing 20 of 26.
As the comparator · 15 — what is tested is compared with Pyrazinamide
- Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06192160Written as Pyrazinamide
- Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis MeningitisNot yet recruitingPhase 2BioVersys AGNCT07350174Written as HRZE
- BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)CompletedPhase 1/2Michael HoelscherNCT04044001Written as Rifafour e-275®
- Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05221502Written as RHEZ
- Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary TuberculosisActive, not recruitingPhase 2Global Alliance for TB Drug DevelopmentNCT06058299Written as HRZE
- A Pan-TB Regimen Targeting Host and MicrobeActive, not recruitingPhase 2/3The Aurum Institute NPCNCT05686356Written as Rifafour
- Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline CohortActive, not recruitingPhase 3Beijing Chest HospitalNCT06081361Written as Pyrazinamide
- Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of CareCompletedPhase 3Wits Health Consortium (Pty) LtdNCT04062201Written as Pyrazinamide Oral Product
- Early Bactericidal Activity of TBA-7371 in Pulmonary TuberculosisCompletedPhase 2Bill & Melinda Gates Medical Research InstituteNCT04176250Written as HRZE
- An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary TuberculosisCompletedPhase 2GlaxoSmithKlineNCT03557281Written as Rifafour e-275
- Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary TuberculosisCompletedPhase 2TASK Applied ScienceNCT05896930Written as Rifafour e-275
- Efficacy of HUEXC030 in Subjects With Pulmonary TuberculosisCompletedPhase 2/3Orient Pharma Co., Ltd.NCT02467608Written as HRZE
- Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTBStatus unknownNot applicableFifth Affiliated Hospital, Sun Yat-Sen UniversityNCT04187469Written as Rifampicin,Isoniazid,Pyrazinamide,Ethambutol
- A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)CompletedPhase 2Qurient Co., Ltd.NCT03563599Written as Rifafour e-275
- Phase 2a EBA Trial of AZD5847CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01516203Written as Ethambutol, isoniazid, pyrazinamide, rifampin
Codes
What other systems call Pyrazinamide · ClinicalTrials.gg INT008132
- MeSH (NLM) D011718PyrazinamideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2KNI5N06TIPYRAZINAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 8987Confirmed FDA, Wikidata
- Wikidata Q417571pyrazinamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29395PyrazinamideOne source FDA
- DrugBank DB00339One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D011718 | Pyrazinamide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2KNI5N06TI | PYRAZINAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 8987 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417571 | pyrazinamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29395 | Pyrazinamide | One source FDA |
| DrugBank | DB00339 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.